Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.

[1]  Silvia Rossi,et al.  Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study. , 2014, The Lancet. Oncology.

[2]  M. Coleman,et al.  Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. , 2014, The Lancet. Oncology.

[3]  S. Chevret,et al.  Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  X. Troussard,et al.  Unbiased estimates of long‐term net survival of hematological malignancy patients detailed by major subtypes in France , 2013, International journal of cancer.

[5]  R. Advani,et al.  Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Sankila,et al.  Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study , 2013, Haematologica.

[7]  M. Gerken,et al.  Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry , 2012, Annals of Hematology.

[8]  Hermann Brenner,et al.  Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. , 2011, The oncologist.

[9]  H. Brenner,et al.  Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. , 2009, The oncologist.

[10]  F. Berrino,et al.  Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.

[11]  Christine F. Wogan,et al.  Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Berrino,et al.  Manual for coding and reporting haematological malignancies. , 2010, Tumori.

[13]  H. Kantarjian,et al.  Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. , 2009, Hematology/oncology clinics of North America.

[14]  H. Brenner,et al.  Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. , 2008, Blood.

[15]  G. Schwarzer,et al.  Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. , 2007, The Cochrane database of systematic reviews.

[16]  J. Armand,et al.  The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib. , 2007, The oncologist.

[17]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[18]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[19]  R. Gascoyne,et al.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Angela Montanari,et al.  Comparison of Four Methods for Estimating Complete Life Tables from Abridged Life Tables Using Mortality Data Supplied to EUROCARE-3 , 2005 .

[21]  H. Brenner,et al.  Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. , 2004, European journal of cancer.

[22]  Mike Quinn,et al.  Standard cancer patient population for age standardising survival ratios. , 2004, European journal of cancer.

[23]  Paul W Dickman,et al.  Regression models for relative survival , 2004, Statistics in medicine.

[24]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[25]  D. Figgitt,et al.  Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. , 2003, Drugs.

[26]  R. Pazdur,et al.  Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. , 2002, The oncologist.

[27]  H. Brenner,et al.  Up-to-date long-term survival curves of patients with cancer by period analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[29]  V. Devita,et al.  Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. , 1980, Annals of internal medicine.